Porcine Parvovirus VP2 Subunit Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) face challenges such as incomplete inactivation of PPV, lack of cross-protection against heterologous strains, and inadequate protection for breeding age gilts and fetuses, with recombinant subunit vaccines showing poor immunogenicity and safety concerns.
Innovation Solution
Development of a recombinant subunit vaccine comprising PPV VP2 antigen, which is safe and efficacious in preventing viremia and infection in fetuses, offering broad protection against heterologous strains and reducing the need for extensive inactivation processes, combined with a PRRSV vaccine to address reproductive disease in pregnant swine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If recombinant subunit vaccines are used, then production safety and reduced inactivation processes are improved, but immunogenicity and cross-protection are worsened
Solution Approach 1:
The patent divides the viral protein into specific functional segments (VP2 subunit) that retain immunogenicity while improving safety. By isolating and expressing only the necessary viral protein subunit rather than using whole virus, the patent achieves production safety while maintaining immunogenicity through proper protein folding and conformational integrity.
Solution Approach 2:
The patent employs parameter changes in protein expression systems (cell type, temperature, media composition) to optimize the immunogenicity of the recombinant VP2 protein. By controlling expression parameters to achieve proper protein folding, glycosylation, and conformational structure, the patent maintains high immunogenicity despite using recombinant technology.
2Reliability
If whole virus vaccines are used, then immunogenicity is improved, but safety concerns and inactivation requirements are worsened
Solution Approach 1:
The patent extracts and isolates the specific VP2 protein subunit from the whole virus, removing all harmful viral components while retaining the immunogenic epitopes. This extraction approach eliminates safety concerns associated with live or inactivated whole virus vaccines while preserving immunogenicity through the isolated protein's conformational integrity.
Solution Approach 2:
The patent creates a molecular copy of the viral VP2 protein through recombinant DNA technology, producing the protein in host cells without using actual viral material. This copying approach eliminates all safety hazards of working with live virus while maintaining immunogenicity through accurate protein sequence and conformational replication.
3Adaptability or versatility
If heterologous virus strains are used, then cross-protection is improved, but vaccine specificity and strain matching are worsened
Solution Approach 1:
The patent designs the recombinant VP2 protein with conserved epitopes that are common across different porcine parvovirus strains. By focusing on universally conserved protein regions rather than strain-specific variants, the vaccine achieves cross-protection against heterologous strains while maintaining manufacturing precision through standardized protein expression protocols.
Data Source
AI summary
The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.